IndustryCompany release

ARS Pharma reports $33.4M neffy US sales in Q3 as market share reaches 5%

🇺🇸 ARS Pharmaceuticals, Inc. (SPRY) · Thu 05 Nov 2026

ARS Pharmaceuticals posted $37.7M total third-quarter revenue, cut SG&A sharply and said interim Phase 2b data for ARS-2 in chronic spontaneous urticaria flares are due in Q1 2027.

ARS Pharmaceuticals reported third-quarter 2026 results on 5 November, with total revenue of $37.7M. Of that, $33.4M came from US net sales of neffy, its needle-free epinephrine nasal spray for severe allergic reactions.

The company said neffy's overall US market share rose to 5%. It also reported a sharp reduction in selling, general and administrative (SG&A) expenses. The summary available does not give the size of the cut or the comparison period.

ARS Pharma maintained its goal of reaching cash flow breakeven by the end of 2027. It also named a new chief medical officer and a new chief legal officer. Names and start dates were not included in the material available.

On the pipeline, interim Phase 2b data for ARS-2 in chronic spontaneous urticaria flares are expected in the first quarter of 2027. No further trial details were provided in the information reviewed.

What it means for your team

  • Market-access teams can track neffy's 5% overall US share as an early indicator of how a needle-free epinephrine option is being taken up against injectable devices.
  • The Q1 2027 interim Phase 2b readout for ARS-2 in chronic spontaneous urticaria flares marks the next clinical milestone to watch for the company.
  • Leadership changes in the medical and legal functions may be relevant for teams that liaise with ARS Pharma on safety, medical or compliance matters.

Company's press release (SEC filing): ARS Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (ARS Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →